Business Context and Reporting Period
Company: eHealth, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026 (Second Quarter of Fiscal Year 2026)
Business Overview: eHealth operates a leading private health insurance marketplace, providing consumer engagement and enrollment solutions for Medicare, individual, family, small business, and ancillary health insurance products. The company utilizes an omnichannel platform combining self-service online tools with licensed benefit advisors.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenue | $33,566 | $60,782 | $121,584 | $173,901 |
| Net Loss | $(23,595) | $(17,398) | $(28,309) | $(15,448) |
| Net Loss Attributable to Common Stockholders | $(37,511) | $(29,783) | $(55,618) | $(39,755) |
| Loss Per Share (Basic & Diluted) | $(1.18) | $(0.98) | $(1.77) | $(1.32) |
| Operating Cash Flow (6 Months) | $30,810 | $35,917 | - | - |
| Cash & Cash Equivalents (End of Period) | $69,681 | - | - | - |
| Short-Term Marketable Securities | $31,367 | - | - | - |
| Long-Term Debt | $114,608 | - | - | - |
| Convertible Preferred Stock | $406,283 | - | - | - |
Note: Q2 2025 comparative balance sheet data is not provided in the text; only income statement and cash flow comparisons are available.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 45% year-over-year in Q2 2026 ($33.6M vs. $60.8M) and 30% for the six-month period. This was driven primarily by a 46% drop in Medicare segment commission revenue due to intentional reductions in variable marketing spend and regulatory impacts on Medicare Part D plans.
- Approved Members: Total approved members declined 36% in Q2 2026 compared to Q2 2025. Medicare Advantage and Supplement approvals dropped 45%, while Medicare Part D approvals fell 80% due to regulatory shifts.
- Cost Reductions: The company implemented a workforce reduction of approximately 14% in Q1 2026. Consequently, Customer Care and Enrollment expenses decreased 20% in Q2, and General and Administrative expenses decreased 28%.
- Restructuring Charges: The company recorded $6.4 million in impairment, restructuring, and other charges for the six months ended June 30, 2026, primarily related to employee termination benefits from the workforce reduction. This compares to $1.6 million in the same period in 2025.
- Debt Financing: In December 2025, the company entered a new $125 million asset-based revolving credit facility, replacing a previous term loan. As of June 30, 2026, the carrying value of this debt was $114.6 million.
Guidance, Outlook, and Risks
- Strategic Initiatives: Management launched a "lifetime advisory model" in Q2 2026 to improve member retention and lifetime value. The company is also diversifying product offerings, including final expense insurance and Individual Coverage Health Reimbursement Arrangements (ICHRA).
- Seasonality: The business is highly seasonal, with the majority of commission revenue recognized in Q4 due to the Medicare Annual Enrollment Period (AEP) and Q1 due to the Medicare Advantage Open Enrollment Period (OEP). Q2 is typically a lower-volume period focused on existing member engagement.
- Legal Proceedings: A significant qui tam action under the Federal False Claims Act was unsealed in May 2025, with the U.S. Attorney's Office intervening in part. The court denied motions to dismiss in March 2026, and discovery is ongoing. The company faces potential treble damages and civil penalties.
- Liquidity Covenants: The company has historically failed to meet certain Minimum Asset Coverage and Minimum Liquidity Amount covenants under its Series A Preferred Stock agreement with H.I.G. Capital, granting the investor additional governance rights. However, as of June 30, 2026, the company was in compliance with the amended liquidity covenant requiring unrestricted cash of at least $45 million.
- Regulatory Risks: The company faces ongoing risks related to changes in Medicare regulations, carrier relationships, and the potential impact of government shutdowns on payment timing.
Investor Verification Checklist
- Revenue Recognition Assumptions: Verify the stability of the "constrained lifetime value" (LTV) assumptions used to recognize commission revenue, particularly given the decline in approved members and changes in retention rates.
- Legal Exposure: Monitor the status of the Federal False Claims Act litigation and any potential settlement amounts or regulatory penalties.
- Covenant Compliance: Confirm continued compliance with the liquidity covenants in the H.I.G. Investment Agreement and the Revolving Credit Facility to avoid increased dividend rates or default.
- Carrier Concentration: Assess the impact of revenue concentration, as Humana, UnitedHealthcare, and Aetna collectively represented a significant portion of revenue (Humana 34%, UnitedHealthcare 29% of receivables).
- Cost Savings Realization: Track the actual realization of cost savings from the 14% workforce reduction and its impact on future operating margins.